2024 ISV WEBINAR SERIES
The International Society for Vaccines (ISV) is excited to announce the monthly ISV Webinar Series. Each month ISV will host a webinar featuring a compelling new speaker and topic. Participation is free and no prerequisites are required. The webinars will be hosted via Zoom and you may join by simply clicking the button or link below.
23 JANUARY 2024 CHALLENGES IN THE DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE
Dr. Peter Palese
Icahn School of Medicine at Mount Sinai
Chair: Ted Ross, Cleveland Clinic Florida
Organizers: Lars Frelin, Karolinska Institutet, Lenny Moise, SeromYx,
Ted Ross, Cleveland Clinc Florida
Dr. Palese is a Professor of Microbiology at the Icahn School of Medicine at Mount Sinai. His research is in the area of RNA-containing viruses with a special emphasis on influenza viruses. Specifically, he established the first genetic maps for influenza A, B, and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). He was also a pioneer in the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. An improvement of this technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent, but extinct, 1918 pandemic influenza virus. His recent work in collaboration with Garcia-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host. Most recently in collaboration with Adolfo García-Sastre and Florian Krammer he has been involved in the development of universal influenza virus vaccines and SARS-CoV-2 vaccines and of their variants of concern (VOC).